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Background: Protection of low-density lipoproteins (LDL) against oxidative modiﬁcation is a key anti-
atherosclerotic property of high-density lipoproteins (HDL). This study evaluated the predictive value
of the HDL antioxidative function for cardiovascular mortality, all-cause mortality and chronic graft
failure in renal transplant recipients (RTR).
Methods: The capacity of HDL to inhibit native LDL oxidation was determined in vitro in a prospective
cohort of renal transplant recipients (RTR, n ¼ 495, median follow-up 7.0 years).
Results: The HDL antioxidative functionality was signiﬁcantly higher in patients experiencing graft
failure (57.4 ± 9.7%) than in those without (54.2 ± 11.3%; P ¼ 0.039), while there were no differences for
cardiovascular and all-cause mortality. Speciﬁcally glomerular ﬁltration rate (P ¼ 0.001) and C-reactive
protein levels (P ¼ 0.006) associated independently with antioxidative functionality in multivariate
linear regression analyses. Cox regression analysis demonstrated a signiﬁcant relationship between
antioxidative functionality of HDL and graft failure in age-adjusted analyses, but signiﬁcance was lost
following adjustment for baseline kidney function and inﬂammatory load. No signiﬁcant association was
found between HDL antioxidative functionality and cardiovascular and all-cause mortality.
Conclusion: This study demonstrates that the antioxidative function of HDL (i) does not predict car-
diovascular or all-cause mortality in RTR, but (ii) conceivably contributes to the development of graft
failure, however, not independent of baseline kidney function and inﬂammatory load.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
High density lipoprotein particles possess a number of anti-
atherosclerotic functionalities such as promoting cholesterol
efﬂux from macrophage foam cells or protecting low density lipo-
proteins (LDL) against oxidative modiﬁcation [1e3], a major initi-
ating factor in the process of atherosclerotic lesion development
[4]. Indeed, large epidemiological studies in the general popula-
tion demonstrated that plasma levels of HDL cholesterol (HDL-C)
can serve as a biomarker for the atheroprotective potential of HDLenter for Liver, Digestive, and
ngen, Hanzeplein 1, 9713 GZ
.
r Ireland Ltd. This is an open acces[5,6]. However, recent genetic studies as well as pharmacological
intervention trials indicated that HDL-C levels as such do not uni-
formly predict cardiovascular disease (CVD) risk [2]. The focus in
the cardiovascular ﬁeld is therefore currently shifting from HDL-C
quantity determinations to efforts to measure the quality of HDL,
i.e. the functional properties of these lipoproteins [1,2,7].
Renal transplant recipients (RTRs) have an increased risk of
atherosclerosis formation, resulting in a 4e6 fold higher CVD risk
[8]. In addition, transplant vasculopathy, an atherosclerotic process
of the vasculature of the transplanted kidney is a major cause for
chronic renal transplant dysfunction, leading to graft failure [9,10].
This is a highly relevant clinical issue, since 5 years after trans-
plantation about 50% of the patients have developed transplant
vasculopathy, a number even increasing to 90% after 10 years [9].
However, especially in this group of patients, classical risk factors
including HDL-C concentrations do not fully explain the increase in
atherosclerosis risk [9], making it likely that changes in functionals article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Therefore, the aim of this study was to evaluate the predictive
value of a selected anti-atherosclerotic key function of HDL, namely
its antioxidative potential, for the risk of future CVD mortality, all-
cause mortality and graft failure in a well-characterized cohort of
renal transplant recipients. Our data demonstrate that a contribu-
tion of the anti-oxidative function of HDL especially to the devel-
opment of graft failure is conceivable, however, not independent of
baseline kidney function and inﬂammatory load.
2. Materials and methods
For an extended description please see online supplement.
2.1. Study design and study population
For this prospective study we used an established patient cohort
of adult renal transplant recipients from the outpatient clinic of the
UMCGwho have visited the hospital between August 2001 and July
2003 [11,12]. The study was approved by the local Medical Ethics
Committee (METc2001/039) and written informed consent was
obtained from all participants. All patients had a functioning renal
graft with no complications for at least 1 year to exclude early
immune-mediated rejection as a potential confounding factor. Pa-
tients with other comorbidities such as endocrine abnormalities
other than diabetes, congestive heart failure or malignant disease
were excluded. All relevant patient characteristics were collected
from the “Groningen Renal Transplant Database”, medical records
and with help of a self-report questionnaire. Of the 847 eligible
patients, 606 volunteered to participate and were included in the
cohort. Plasma samples were available from 517 patients, of which
22 were excluded due to acute inﬂammation at the time of blood
sampling as evidenced by high CRP levels (above 15 mg/l), leaving
495, in which the antioxidative functionality of HDL was deter-
mined. In an alternative set of analyses (please see online
supplement) patients with CRP levels above 10 mg/l were
excluded (n ¼ 65), leaving n ¼ 454 patients for analysis.
2.2. Isolation of HDL and measurement of antioxidative
functionality
To determine HDL-mediated protection against LDL oxidation, a
previously published method was used [13]. Brieﬂy, HDL was iso-
lated by precipitation of apoB-containing lipoproteins as described
[13,14]. For the antioxidation assay 2% of individual HDL prepara-
tions were added to native, unoxidized LDL particles (100 mg/dl
ﬁnal protein concentration), after which oxidation was induced by
6.3 ml of 2.5 mM AAPH (2,20-azobis [2-amidinopropane] dihydro-
chloride) followed by incubation at 37 C for 10 h. After that thio-
barbituric acid reactive substances (TBARS) were determined as a
measure for the degree of LDL oxidation as detailed previously [13].
The HDL antioxidative capacity was calculated as the percent
reduction in TBARS formation obtained with an individual HDL
sample relative to a reaction to which only LDL and AAPH but no
HDL had been added [13]. Higher values thus indicate better pro-
tection against LDL oxidation. The antioxidation assay for all sam-
ples was carried out at the same time and with the same badges of
reagents to limit potential variation due to different assay condi-
tions. We also compared apoB-depleted plasma with (i) respective
lipoprotein-free plasma preparations (Supplemental ﬁgure I) and
(ii) HDL isolated by sequential density ultracentrifugation
(Supplemental ﬁgures II and III). These combined data indicate that
with the sample preparation method used in our study the
antioxidative function is to a substantial part due to the presence of
HDL. The storage time of the samples was not statisticallyassociated with the results of the antioxidative function assay
indicating that different length of storage is not a confounding
factor.
2.3. Primary end points
The main outcome measure of this study is the antioxidative
functionality of HDL, the primary end points are cardiovascular
mortality, all-cause mortality, and graft failure. Graft failure was
deﬁned as return to dialysis therapy or retransplantation. A sur-
veillance system ensured information on patient status and cause
of death between inclusion and up to the year 2009 [12].
2.4. Statistical analysis
All statistical analyses were conducted using SPSS 20. Normally
distributed continuous variables are given as mean ± standard
deviation, continuous variables with a skewed distribution as me-
dian [25the75th percentile] and categorical variables by absolute
numbers (percentages). Overall trends between antioxidative
functionality and the three primary endpoints were tested for
signiﬁcant differences using student's t-test. Renal transplant re-
cipients were divided into tertiles according to the antioxidative
functionality of HDL (low, medium, and high) and stratiﬁed for
gender. Baseline characteristics of the patients were analyzed and
tested for differences among these three groups. One-way analysis
of variance followed by Bonferroni post hoc test was used for
normally distributed variables and the Kruskal-Wallis test followed
by Mann-Whitney U test for variables with a skewed distribution.
The Chi-square test was used to compare categorical data. Multi-
variate linear regression analyses were performed with inclusion of
parameters with a P-value 0.1 between the tertiles of HDL anti-
oxidative capacity into the model and by eliminating by step-by-
step backward regression (P  0.05). Subsequently, multivariate
Cox regression analysis models were created to estimate the hazard
ratios (HRs) and 95% CIs for all-cause mortality, cardiovascular
mortality and graft failure. HRs are reported per 1-SD increase with
95% conﬁdence intervals (CIs). Power calculations indicated that
the minimum detectable HR based on an assumption of 90% power
and a two-sided alpha signiﬁcance of 0.05 was 0.77 for CVD mor-
tality, 0.83 for overall mortality, and 0.75 for graft failure. A two-
sided P-value of 0.05 was considered statistically signiﬁcant.
3. Results
In this study the predictive value of HDL antioxidative func-
tionality on the survival of patients as well as their kidney grafts
was analyzed in 495 renal transplant recipients (mean age
51.6 ± 12.0; 54%male). Patients had a median follow-up of 7.0 years
[6.3e7.5 years]. Within this period, 102 (21%) patients died, which
was attributable to CVD in 54 patients (11%). A total of 46 (9%)
patients experienced renal graft failure.
First, the antioxidative functionality at baseline was compared
between patients with or without subsequent cardiovascular death,
all-cause mortality and graft failure during follow-up. At baseline,
patients who died due to cardiovascular causes did not have a
signiﬁcantly different antioxidative function (56.0 ± 9.7%)
compared to those not experiencing cardiovascular death
(54.3 ± 11.4%; P ¼ 0.236). Further, in patients who died due to any
cause, antioxidative functionality was also not signiﬁcantly
different (56.1 ± 9.1%) compared to those who survived
(54.0 ± 11.6%; P ¼ 0.095). However, renal transplant recipients who
did not experience graft failure had a signiﬁcantly lower anti-
oxidative HDL function (54.2 ± 11.3%), compared to those with
subsequent graft failure (57.4 ± 9.7%; P ¼ 0.039). When using a cut-
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statistically signiﬁcant (please see online supplement for details).
Next, baseline characteristics of the patients were analyzed. For
this purpose patients were divided into tertiles, based on their HDL
antioxidative functionality stratiﬁed for gender: low 44.0%
[39.4e48.9], medium 55.7% [53.2e57.9] and high 64.4%
[61.5e67.6]. Table 1 shows the relevant baseline parameters, for the
complete data set see online supplement (Supplemental Table I).
Age of the renal transplant recipients was not found to differ ac-
cording to antioxidative functionality. Patients with higher anti-
oxidative capacity had higher plasma levels of total cholesterol
(P ¼ 0.035) and triglycerides (P ¼ 0.006). Apolipoprotein A-I, a
major protein component of HDL, was inversely related to anti-
oxidative function (P ¼ 0.044). Higher levels of hsCRP, thus higher
inﬂammatory load, were found to be associated with better anti-
oxidative capacities of HDL (P ¼ 0.006). Differences in insulin
concentration and insulin resistance (HOMA-IR) among the
different groups divided according to antioxidative functionality
were also detected. In addition, better anti-oxidative function was
associated with lower glomerular ﬁltration rate (eGFR), thus
decreased kidney function.
Then multivariate linear regression analyses were performed to
assess which variables are independently associated with anti-
oxidative functionality of HDL. All parameters found to show a
difference of P < 0.10 between the tertiles of HDL antioxidative
capacity, were included in the analysis (Table 2). Antioxidative
functionality had an independent association with eGFR, gender,
plasma hsCRP and insulin concentration, however, the R2 of the
ﬁnal model was 0.07.
Further, multivariate Cox regression analysis was carried out to
obtain proportional hazard ratios and evaluate the independent
contribution of antioxidative functionality to the risk of mortality
and graft failure (Table 3). Antioxidative function of HDL did not
have a signiﬁcant relationship with all-cause (P ¼ 0.108) or speciﬁc
cardiovascular mortality (P ¼ 0.276), a ﬁnding remaining un-
changed after correction for age, gender, eGFR and CRP. On the
other hand, antioxidative capacity was found to be signiﬁcantly
associated with the risk of graft failure (P ¼ 0.038). After adjust-
ment for age, this association did not change appreciably
(P ¼ 0.035). After additional adjustment for gender, this association
was still strong, but lost formal statistical signiﬁcance (P ¼ 0.056).
Following further adjustment for eGFR, and CRP the association
with graft failure is lost.
Taken together, these results indicate that the antioxidativeTable 1
Most relevant characteristics of renal transplant recipients divided into tertiles based on
Parameters Tertiles according to antioxidative funct
Low Me
HDL Antiox. Function (%) 44.0 [39.4e48.9] 55.
Age of patient, years 52.7 [43.8e60.2] 53.
Male gender, n (%) 90 (54.5) 90
BMI, kg/m2 25.7 ± 4.4 25.
Total Cholesterol, mmol/L 5.5 ± 1.0 5.6
Apolipoprotein A-I, g/L 1.6 ± 0.3 1.6
LDL Cholesterol, mmol/L 3.4 ± 1.0 3.6
HDL Cholesterol, mmol/L 1.1 ± 0.3 1.1
Triglycerides, mmol/L 1.8 [1.3e2.6] 1.8
Insulin, mmol/L 12.1 [8.7e17.9] 10.
HOMA-IR 2.4 [1.7e4.0] 2.0
hsCRP, mg/L 1.5 [0.6e3.4] 2.0
eGFR, mL/min/1.73m2 49.2 ± 16.6 48.
a Tertile signiﬁcantly different from ﬁrst (low) tertile, P < 0.05.
b Tertile signiﬁcantly different from ﬁrst (low) tertile, P < 0.01.
c Tertile signiﬁcantly different from second (medium) tertile, P < 0.05.
d Tertile signiﬁcantly different from second (medium) tertile, P < 0.01. Data are givenfunctionality of HDL might contribute to the development of graft
failure in RTR, however, not independent of eGFR and CRP.
4. Discussion
The results of this prospective study suggest that, at least in RTR,
the antioxidative functionality of HDL might not have the potential
to serve as a clinically relevant predictive biomarker for cardio-
vascular disease, all-cause mortality or the development of chronic
graft failure. RTR were chosen, since in this patient group the
pathophysiological mechanisms of CVD but also of chronic
atherosclerosis-mediated graft failure are not well deﬁned, how-
ever, traditional risk factors and speciﬁcally HDL-C cannot fully
explain the increased risk [9,15,16]. In our reasoning, these obser-
vations increased the probability for changes in HDL function to
have an impact. The most interesting ﬁnding of our study is that
baseline antioxidative functionality predicts graft failure in RTR, at
least in crude and age-adjusted models. Unexpectedly though, a
better antioxidative HDL functionwas associated with a higher risk
of graft failure. A potential explanation could be derived from the
observation that this correlation was lost once either an even
stricter cut-off value for plasma CRP was used (10 mg/l instead of
15 mg/l, for data please see online supplement) or after correcting
for potential confounders, most importantly eGFR and CRP. Both, a
decline in kidney function and an increased inﬂammatory load are
conditions of increased in vivo oxidative stress [17,18]. It is pri-
marily counterintuitive that higher oxidative stress is associated
with better anti-oxidative function of HDL. However, this associa-
tion could be conceivably caused by a compensatory response
namely an attempt to increase antioxidative defense mechanisms
to meet the increased demand as e.g. has been shown in smokers
[19]. That this attempt remains unsuccessful could be due to a
decrease in other HDL functions in proinﬂammatory conditions,
such as cholesterol efﬂux and reverse cholesterol transport [2,20].
The plausibility of these considerations is clinically supported by a
study showing that high CRP levels offset the tight inverse corre-
lation between HDL-C and risk of atherosclerotic cardiovascular
disease; the authors also interpreted their ﬁndings as indicative of
inﬂammation decreasing the atheroprotective functionality of HDL
[21]. However, to formally prove this point further studies are
required. Also, it should be noted that an absolute number of 46
patients with graft failure is relatively low for statistical analysis;
therefore, although in itself robust, the results should be treated
with caution.HDL antioxidative functionality and stratiﬁed for gender.
ionality P Value
dium High
7 [53.2e57.9]b 64.4 [61.5e67.6]b,d <0.001
8 [42.3e61.1] 52.8 [44.1e59.9] 0.705
(54.2) 89 (54.3) 1.000
8 ± 4.0 26.3 ± 4.3 0.469
± 0.9 5.8 ± 1.2 0.035
± 0.3 1.5 ± 0.3c 0.044
± 0.9 3.7 ± 1.1 0.098
± 0.3 1.1 ± 0.3 0.125
[1.4e2.3] 2.1 [1.5e2.9]a,d 0.006
1 [7.7e12.9]b 10.9 [7.7e14.8]a 0.003
[1.5e2.9]b 2.3 [1.5e3.2] 0.006
[0.9e4.4]a 2.2 [1.1e5.3]b 0.006
9 ± 15.4 43.7 ± 14.9b,d 0.002
either as mean ± SD or median [25the75th percentile].
Table 2
Variables independently associated with antioxidative functionality of HDL.
Beta 95% CI Standardized beta P Value
eGFR, mL/min/1.73m2 0.103 [0.164; 0.042] 0.146 0.001
Male gender, n (%) 3.083 [1.150; 5.017] 0.137 0.002
hsCRP, mg/L 2.621 [0.739; 4.504] 0.121 0.006
Insulin, mmol/L 5.655 [9.838; 1.472] 0.116 0.008
Variables are listed in decreasing order of strength of association according to the value of the standardized beta.
Table 3
Hazard ratios for graft failure, cardiovascular mortality and all-cause mortality by antioxidative functionality of HDL.
Graft failure
(46 events)
Cardiovascular mortality
(54 events)
All-cause mortality
(102 events)
HR [95%CI] per 1-SD increase P value HR [95%CI] per 1-SD increase P value HR [95%CI] per 1-SD increase P value
Model 1 (crude) 1.03 [1.00e1.06] 0.038a 1.01 [0.99e1.04] 0.276 1.02 [1.00e1.03] 0.108
Model 2 (model 1 þ age) 1.03 [1.00e1.06] 0.035a 1.01 [0.99e1.04] 0.300 1.02 [1.00e1.03] 0.123
Model 3 (model 2 þ gender) 1.03 [1.00e1.96] 0.056 1.01 [0.99e1.04] 0.314 1.02 [1.00e1.03] 0.128
Model 4 (model 2 þ eGFR) 1.01 [0.98e1.04] 0.571 1.01 [0.98e1.03] 0.660 1.01 [0.99e1.03] 0.392
Model 5 (model 3 þ hsCRP) 1.01 [0.98e1.04] 0.535 1.00 [0.98e1.03] 0.832 1.01 [0.99e1.03] 0.514
a Statistically signiﬁcant, P < 0.05.
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enzyme, which is associated with HDL and is involved in modu-
lating LDL oxidation [13,22]. We concluded from a previous study
that increased LCAT activity contributes to an impaired anti-
oxidative functionality of HDL [13]. The activity of LCAT itself is
reduced with impaired kidney function or inﬂammation, both
present in RTR [23,24]. In this scenario a reduced LCAT activity
might result in improved antioxidative functionality of the HDL
particle. However, LCAT levels were not determined in the present
study.
Furthermore, the anti-oxidative function of HDL could be
inﬂuenced by the administered medication. In our study a better
HDL function tended to be associated with the number of anti-
hypertensives as well as the use of calcineurin inhibitors.
Although in the present work for the anti-hypertensive medication
this trend was not conﬁrmed for individual classes of drugs, pre-
vious studies suggested that at least b-blockers, angiotensin con-
verting enzyme inhibitors and angiotensin II receptor 1 antagonists
can reduce oxidative stress and lipid peroxidation [25,26]. Calci-
neurin inhibitors on the other hand are rather thought to induce
oxidative stress [27e29]. Taken together, although the association
did not reach the level of statistical signiﬁcance, it can not be
excluded at present that medication contributes to the observa-
tions made in our study and, in a broader perspective, to ﬁndings in
cohorts of RTR in general.
Another ﬁnding of our study worthwhile to point out is the U-
shaped relationship between the HDL anti-oxidative function and
HOMA-IR. Since blood glucose values (Supplemental table I) did not
differ between the different tertiles of HDL anti-oxidative func-
tionality, this relationship seems primarily due to differences in
circulating insulin levels. HDL has been shown to impact both, in-
sulin secretion by pancreatic b-cells [30] as well as glucose uptake
in the periphery by skeletal muscle [31]. However, the current
study was not designed to speciﬁcally investigate a relationship
between HDL function and parameters of glucose metabolism;
therefore, a potential causality of our observation as well as the
delineation of impacting factors remain unresolved. Future studies
with a speciﬁc focus on glucose metabolism parameters would be
required to clarify these points.
In general, studies addressing the prospective value of HDL
function measurements on clinically relevant outcomes are scarce.
There are thus far only two reports evaluating a differentfunctionality of HDL, namely cholesterol efﬂux, in predicting future
cardiovascular mortality in the general population. Interestingly, in
one the authors found, also against expectations, that a high
cholesterol efﬂux capacity was associated with an increased risk for
CVD and death [32], while in the other better efﬂux at baseline
predicted lower CVD risk during follow-up [33]. Clearly, more
research is needed to understand the complex relationship be-
tween factors determining HDL quality independent of HDL-C
levels and the clinical signiﬁcance of HDL function in different
relevant settings, including changes in response to therapeutic
intervention. It needs to be taken into account for the interpreta-
tion of HDL function studies that no gold standards are available for
respective assays and not even for methods to isolate HDL [2].
Therefore, interpretation of each individual study depends on the
assay conditions applied, the respective experimental read-outs
and the methodology to isolate HDL, which are complex particles
differing in size and carrying a diverse lipid and protein cargo [2]. In
the present study we decided to use plasma after precipitation of
apoB-containing lipoproteins, similar to studies by other groups
addressing HDL anti-oxidative properties [14]. This method is
suitable for large numbers of clinical samples, however, also leaves
other components of plasma. At present we can not, based on the
design of our study, formally exclude that these might contribute to
the associations found in our analyses.
In conclusion, our study shows that the antioxidative func-
tionality of HDL might not be a clinically relevant parameter to
predict future cardiovascular or all-causemortality in RTR as well as
chronic graft failure. Graft failure was predicted in these patients to
a certain extent, however, not independent of baseline kidney
function and inﬂammatory load, and in a fashion that might be
opposite to expectations. More research, also including other bio-
logically relevant functions of HDL will be required to delineate the
prospective value of HDL function for CVD and graft failure in RTR.
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